$65.20
-0.74[-1.12%]
At close: Apr 30
$65.20
0[0.00%]
After Hours: 6:36PM EDT
Gilead Sciences
(NASDAQ:GILD)Latest News for Gilead Sciences Stock (NASDAQ:GILD)
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
Monday, April 29, 2024
Friday, April 26, 2024
- Gilead Sciences Unusual Options ActivityBenzinga Insights - 4 days ago
- TD Cowen Maintains Buy on Gilead Sciences, Lowers Price Target to $85Benzinga Newsdesk - 4 days ago
- Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $78Benzinga Newsdesk - 4 days ago
- RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $74Benzinga Newsdesk - 4 days ago
- FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV; Perinatal Guidelines Recognize Biktarvy As Alternative Regimen For Use During Pregnancy And For Those Trying To ConceiveBenzinga Newsdesk - 4 days ago
- Needham Reiterates Hold on Gilead SciencesBenzinga Newsdesk - 4 days ago
Thursday, April 25, 2024
- Gilead Sciences shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.Benzinga Newsdesk - 5 days ago
- Gilead Sees FY24 Adj. EPS $3.45-$3.85Benzinga Newsdesk - 5 days ago
- Gilead Sciences Sees FY24 Sales $27.1B-$27.5B Vs $27.982BBenzinga Newsdesk - 5 days ago
- Gilead Sciences Q1 2024 Adj EPS $(1.32) Beats $(1.49) Estimate, Sales $6.10B Miss $6.34B EstimateBenzinga Newsdesk - 5 days ago
- Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?Piero Cingari - 5 days ago
- Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend YieldsAvi Kapoor - 5 days ago
- US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says AnalystShanthi Rexaline - 5 days ago
Wednesday, April 24, 2024
Sunday, April 21, 2024
Friday, April 19, 2024
- Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024Benzinga Newsdesk - Apr 19, 2024, 4:43PM
- The Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsBenzinga Insights - Apr 19, 2024, 3:00PM
- Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price TargetBenzinga Newsdesk - Apr 19, 2024, 10:57AM
- FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer TherapiesVandana Singh - Apr 19, 2024, 9:28AM
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
Friday, April 05, 2024
Wednesday, April 03, 2024
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 3, 2024, 1:35PM
- CORRECTION: Wells Fargo On Mar. 4 Lowered Gilead PT From $84 To $78Benzinga Newsdesk - Apr 3, 2024, 11:55AM
- If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 TodayBenzinga Insights - Apr 3, 2024, 10:30AM
Monday, April 01, 2024
Thursday, March 28, 2024
- Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's WhyVandana Singh - Mar 28, 2024, 12:39PM
- FDA Expands Indication For Gilead's Vemlidy To Treat Chronic HBV Infection In Pediatric PatientsBenzinga Newsdesk - Mar 28, 2024, 8:33AM
- Gilead, Xilio Enter Exclusive License Deal For Phase 1 Tumor-Activated Il-12 Program, XTX301; Deal Includes $43.5M Upfront, Up To $604M In Additional Contingent PaymentsBenzinga Newsdesk - Mar 28, 2024, 7:04AM
Wednesday, March 27, 2024
Friday, March 22, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Monday, March 11, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
Wednesday, March 06, 2024
- Gilead Sciences, Inc. Announces New Data From Three Studies Evaluating The Efficacy And Safety Profile Of Biktarvy, Demonstrating High Rates Of Viral Suppression In People With HIV And ComorbiditiesHappy Mohamed - Mar 6, 2024, 4:47PM
- Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo TherapyVandana Singh - Mar 6, 2024, 4:30PM
- Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, ToddlersVandana Singh - Mar 6, 2024, 4:21PM
- Gilead and Merck Announce Phase 2 Data Showing An Investigational Oral Once-Weekly Combination Regimen Of Islatravir And Lenacapavir Maintained Viral Suppression At Week 24Benzinga Newsdesk - Mar 6, 2024, 10:26AM
- Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5BBenzinga Newsdesk - Mar 6, 2024, 8:05AM